Chordate Medical Holding AB (publ) ("Chordate") will partner with RQM + in the project to obtain a marketing authorization for the K.O.S treatment for chronic migraine from the US Food and Drug Administration, FDA. RQM + is one of the world's largest regulatory and quality consulting firm focused on medical devices and diagnostics.
"This project is an important step in our strategy to build company value, and it is necessary to choose a competent partner with extensive experience of this type of project, which we get with RQM +", says Anders Weilandt, CEO of Chordate.
As Chordate announced in October 2021, the company has made a strategic decision to initiate a pre-study study to apply for marketing authorization for the K.O.S treatment for chronic migraine with the US Food and Drug Administration, FDA. The pre-study will begin immediately through the collaboration with RQM+ and can be expected to be completed within the first quarter of 2022, when a decision on the choice of strategy can be made.
Information:
This disclosure was submitted for publication, through the contact person below, on December 13th, 2021, at 15:15 am CET.
For more information, please contact:
Anders Weilandt, CEO
Cell: +46 733-874277
e-mail: anders.weilandt@chordate.com
The following documents can be retrieved from beQuoted
Chordate-has-chosen-RQM-to-prepare-a-marketing-authorization.pdf
About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel and Saudi Arabia. Chordate Medical's share is listed on the Nordic Growth Market NGM – SME (ticker: CMH). Read more athttps://www.chordate.com/en/
